(13 April, 2017) Cardiovascular diseases such as myocardial infarction and heart failure still widespread in society causing more than 30% of deaths globally costing approximately €190 billion in Europe alone. Despite medicine’s advances in the field, conventional therapies are still very effective. Commonly used methods of administering medication orally or intravenously allowing the dose to circulate in the bloodstream to reach to heart are still very critical today. The PlumeStars start-up company from Parma founded by professors from the the Department of Food Science and Medicine at the University of Parma was selected along with 18 other partners to join the project “Cupido”, launched in February 2017 (www.cupidoproject.eu) funded by the European Union under the programme Horizon 2020. the aim of Cupido is to create an innovative therapy based on direct pharmaceutical nanotechnology to the cardiovascular system. (Red)
